Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar
By Theresa Schliep · March 14, 2025, 6:52 PM EDT
The Federal Circuit on Friday agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login